Cited by 51Antifungal resistance and susceptibilityFungal Infections and StudiesNeutropenia and Cancer Infections

Galactomannan in Bronchoalveolar Lavage for Diagnosing Invasive Fungal Disease

Affolter, Kristina, Tamm, Michael, Jahn, Kathleen, Halter, Jörg, Passweg, Jakob, Hirsch, Hans H., Stolz, Daiana·2014·American Journal of Respiratory and Critical Care Medicine

Abstract

Rationale: Invasive fungal disease (IFD) is a significant cause of morbidity and mortality in immunocompromised patients. Objectives: We hypothesize that galactomannan (GM), a component of fungal cell wall, as measured in bronchoalveolar lavage (BAL) might be a diagnostic adjunct in hematologic malignancies. Methods: A total of 568 hematologic cases undergoing diagnostic bronchoscopy because of respiratory symptoms and/or suspected IFD between 2009 and 2013 at a tertiary care center in Switzerland were included in this prospective, observational cohort study. We compared accuracy of the BAL GM ELISA determination in predicting IFD as classified by the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group (EORTC/MSG) definition. Measurements and Main Results: BAL GM was positive in 155 cases (29.2%). According to the EORTC/MSG criteria, IFD was classified as possible in 182 (34.3%), probable in 45 (8.5%), and proved in six (1.1%). BAL GM provided 50% sensitivity, 73.0% specificity, 16% positive predictive value, and 93% negative predictive value for diagnosing proven+probable IFD. Results were similar when antifungal treatment and radiologic suspicion of IFD were used as the gold standard. The area under the curve of the receiver operating characteristic curve for the diagnosis of proven+probable IFD was 0.716 (95% confidence interval, 0.638–0.794; P < 0.001). Conclusions: GM in BAL had modest agreement with EORTC/MSG criteria for diagnosing IFD in immunocompromised patients with a high degree of antifungal exposure.

Integrity signals

Registry

Crossref · 10.1164/rccm.201403-0431oc

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Recent studies showed that BAL fluid GM has improved sensitivity compared to serum GM in high-risk patients with IPA, including nonneutropenic patients.

    “Recent studies showed that BAL fluid GM has improved sensitivity compared to serum GM in high-risk patients with IPA, including nonneutropenic patients (88, 114–119).”

    From Aspergillus fumigatus and Aspergillosis in 2019 (2019) · cites this paper as [114]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Affolter, K., Tamm, M., Jahn, K., Halter, J., Passweg, J., Hirsch, H. H., & Stolz, D.
Affiliations
  • Clinic of Pulmonary Medicine and Respiratory Cell Research
  • University Hospital of Basel (CH)
  • University of Basel (CH)
Corresponding author
Stolz, Daiana
Venue
American Journal of Respiratory and Critical Care Medicine
Published
2014-08-01
Volume
190
Issue
3
Pages
309-317
ISSN
  • 1073-449X (ISSN-L)
  • 1535-4970
OpenAlex
W2028931160
Cited by
51
References
26
Citations by year
2026: 1 · 2024: 2 · 2023: 3 · 2022: 1 · 2021: 2 · 2020: 6 · 2019: 4 · 2018: 4 · 2017: 5 · 2016: 3 · 2015: 13 · 2014: 7
FWCI
6.54
Type
journal article
Language
en
Open access
closed
Locations
  • American Journal of Respiratory and Critical Care Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • edoc (University of Basel) (submittedVersion)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Health Sciences › Medicine › Epidemiology › Fungal Infections and Studies
  • Health Sciences › Medicine › Oncology › Neutropenia and Cancer Infections
Keywords
galactomannan, invasive fungal infections, bronchoalveolar lavage, hematologic malignancies, immunocompromised patients, diagnostic accuracy, EORTC/MSG criteria, diagnostic bronchoscopy
MeSH terms
Adult, Antifungal Agents, Bronchoalveolar Lavage Fluid, Bronchoscopy, Female, Galactose, Humans, Male, Mannans, Middle Aged, Prospective Studies, Sensitivity and Specificity, Switzerland, Biomarkers, Logistic Models, Immunocompromised Host, Statistics, Nonparametric, Chemoprevention, Hematologic Neoplasms, Area Under Curve, Invasive Pulmonary Aspergillosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review